AccuStem Sciences, Inc. (ACUT)
OTCMKTS · Delayed Price · Currency is USD
1.910
+0.080 (4.37%)
At close: Aug 7, 2025
AccuStem Sciences Company Description
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care.
It offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant.
The company also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients.
AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.
AccuStem Sciences, Inc.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Wendy Blosser |
Contact Details
Address: 5 Penn Plaza New York, Delaware 10001 United States | |
| Website | accustem.com |
Stock Details
| Ticker Symbol | ACUT |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US00444A1016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Wendy E. Blosser | Chief Executive Officer and Director |
| Gabriele Marco Antonio Cerrone M.B.A. | Executive Chairman of the Board |
| Joe Flanagan | Chief Business Officer |
| Keeren Shah | Chief Financial Officer |